DE112004001520B4 - Verwendung eines Lipidglyzerids festgelegter Struktur zur Herstellung eines Medikamentes zur Behandlung der multiplen Sklerose - Google Patents
Verwendung eines Lipidglyzerids festgelegter Struktur zur Herstellung eines Medikamentes zur Behandlung der multiplen Sklerose Download PDFInfo
- Publication number
- DE112004001520B4 DE112004001520B4 DE112004001520T DE112004001520T DE112004001520B4 DE 112004001520 B4 DE112004001520 B4 DE 112004001520B4 DE 112004001520 T DE112004001520 T DE 112004001520T DE 112004001520 T DE112004001520 T DE 112004001520T DE 112004001520 B4 DE112004001520 B4 DE 112004001520B4
- Authority
- DE
- Germany
- Prior art keywords
- oil
- lipid
- multiple sclerosis
- treatment
- gla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 49
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 title description 7
- 238000004519 manufacturing process Methods 0.000 title description 4
- 150000002632 lipids Chemical class 0.000 claims abstract description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 24
- 125000005313 fatty acid group Chemical group 0.000 claims abstract 2
- 125000001882 gamma-linolenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 18
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 18
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 15
- 230000003902 lesion Effects 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 10
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 4
- 208000018198 spasticity Diseases 0.000 claims description 2
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims 3
- 230000003387 muscular Effects 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 147
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 72
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 72
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 71
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 62
- 239000003921 oil Substances 0.000 description 60
- 235000019198 oils Nutrition 0.000 description 60
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 53
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 34
- 229960002733 gamolenic acid Drugs 0.000 description 34
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- 201000002491 encephalomyelitis Diseases 0.000 description 31
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 31
- 229910052757 nitrogen Inorganic materials 0.000 description 31
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 235000021324 borage oil Nutrition 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 29
- 238000004128 high performance liquid chromatography Methods 0.000 description 29
- 239000011780 sodium chloride Substances 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 25
- 238000003786 synthesis reaction Methods 0.000 description 25
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 235000014113 dietary fatty acids Nutrition 0.000 description 18
- 239000000194 fatty acid Substances 0.000 description 18
- 229930195729 fatty acid Natural products 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 150000004665 fatty acids Chemical class 0.000 description 14
- 239000000377 silicon dioxide Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 13
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 13
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 13
- -1 with β-Avonex ® Proteins 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 12
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 11
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 11
- 235000020778 linoleic acid Nutrition 0.000 description 11
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- BPYWNJQNVNYQSQ-UHFFFAOYSA-N (3-decanoyloxy-2-hydroxypropyl) decanoate Chemical compound CCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCC BPYWNJQNVNYQSQ-UHFFFAOYSA-N 0.000 description 10
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- IPIVAXLHTVNRBS-UHFFFAOYSA-N decanoyl chloride Chemical compound CCCCCCCCCC(Cl)=O IPIVAXLHTVNRBS-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000000278 spinal cord Anatomy 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- DRAWQKGUORNASA-CLFAGFIQSA-N 1,3-dioleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COC(=O)CCCCCCC\C=C/CCCCCCCC DRAWQKGUORNASA-CLFAGFIQSA-N 0.000 description 6
- DRAWQKGUORNASA-UHFFFAOYSA-N Anticancer Glycerol Ester PMV70P691-119 Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCC=CCCCCCCCC DRAWQKGUORNASA-UHFFFAOYSA-N 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 235000007689 Borago officinalis Nutrition 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 235000008524 evening primrose extract Nutrition 0.000 description 5
- 229940089020 evening primrose oil Drugs 0.000 description 5
- 239000010475 evening primrose oil Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000008707 rearrangement Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 5
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 208000016192 Demyelinating disease Diseases 0.000 description 4
- 206010012305 Demyelination Diseases 0.000 description 4
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 240000001890 Ribes hudsonianum Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- CXEMWUYNUIKMNF-UHFFFAOYSA-N tert-butyl 4-chlorosulfonylpiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(S(Cl)(=O)=O)CC1 CXEMWUYNUIKMNF-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 3
- 241000722877 Borago Species 0.000 description 3
- 240000004355 Borago officinalis Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 3
- 235000001466 Ribes nigrum Nutrition 0.000 description 3
- 241001282153 Scopelogadus mizolepis Species 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003210 demyelinating effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 235000004626 essential fatty acids Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940093633 tricaprin Drugs 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- MLQBTMWHIOYKKC-KTKRTIGZSA-N (z)-octadec-9-enoyl chloride Chemical compound CCCCCCCC\C=C/CCCCCCCC(Cl)=O MLQBTMWHIOYKKC-KTKRTIGZSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- DVWSXZIHSUZZKJ-UHFFFAOYSA-N 18:3n-3 Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OC DVWSXZIHSUZZKJ-UHFFFAOYSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- RRUCHHPCCXAUEE-UHFFFAOYSA-N 2-amino-n-[2-oxo-2-(2-oxoethylamino)ethyl]acetamide Chemical compound NCC(=O)NCC(=O)NCC=O RRUCHHPCCXAUEE-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241001072256 Boraginaceae Species 0.000 description 2
- 206010051290 Central nervous system lesion Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 239000001188 FEMA 4487 Substances 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 241000498617 Mucor javanicus Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000219925 Oenothera Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000007844 axonal damage Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- JFRWATCOFCPIBM-UHFFFAOYSA-N gamma-linolenic acid methyl ester Natural products CCCCCC=CCC=CCC=CCCCCC(=O)OC JFRWATCOFCPIBM-UHFFFAOYSA-N 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 235000010598 long-chain omega-6 fatty acid Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- JFRWATCOFCPIBM-JPFHKJGASA-N methyl gamma-linolenate Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(=O)OC JFRWATCOFCPIBM-JPFHKJGASA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- FTVZBLRZKKNUDX-UHFFFAOYSA-N (3-decanoyloxy-2-oxopropyl) decanoate Chemical compound CCCCCCCCCC(=O)OCC(=O)COC(=O)CCCCCCCCC FTVZBLRZKKNUDX-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-YHTMAJSVSA-N (6e,9e,12e)-octadeca-6,9,12-trienoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\CCCCC(O)=O VZCCETWTMQHEPK-YHTMAJSVSA-N 0.000 description 1
- MAAVGFJWXMUHAT-QNEBEIHSSA-N (6z,9z,12z)-octadeca-6,9,12-trienoyl chloride Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(Cl)=O MAAVGFJWXMUHAT-QNEBEIHSSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- RZUYRSAKBYELDE-CLFAGFIQSA-N (9z,30z)-nonatriaconta-9,30-diene-18,20,22-trione Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)CC(=O)CC(=O)CCCCCCC\C=C/CCCCCCCC RZUYRSAKBYELDE-CLFAGFIQSA-N 0.000 description 1
- UBEIMDKGOYBUKT-FLIQGJDUSA-N 1,2,3-trilinolenoylglycerol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC UBEIMDKGOYBUKT-FLIQGJDUSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- PSPVLPOIKNTQGL-UHFFFAOYSA-N 2-tritylpropane-1,2,3-triol Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)(C1=CC=CC=C1)C(CO)(O)CO PSPVLPOIKNTQGL-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- LZSJCSQKHQTZID-HUYIQXHZSA-N DG(18:3n6/0:0/18:3n6) Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(=O)OCC(O)COC(=O)CCCC\C=C/C\C=C/C\C=C/CCCCC LZSJCSQKHQTZID-HUYIQXHZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000002693 Multiple Abnormalities Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001486234 Sciota Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241001125822 Trigla Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- XFEQDRIKSRFJQH-HUYIQXHZSA-N [3-[(6z,9z,12z)-octadeca-6,9,12-trienoyl]oxy-2-oxopropyl] (6z,9z,12z)-octadeca-6,9,12-trienoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(=O)OCC(=O)COC(=O)CCCC\C=C/C\C=C/C\C=C/CCCCC XFEQDRIKSRFJQH-HUYIQXHZSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- 229940094199 black currant oil Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007991 neuronal integrity Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000021542 oral nutrition Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/65—Halogen-containing esters of unsaturated acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
- C07C67/29—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0319358A GB0319358D0 (en) | 2003-08-18 | 2003-08-18 | Treatment of neurodegenerative conditions |
| GB0319358.8 | 2003-08-18 | ||
| GB0410846.0 | 2004-05-14 | ||
| GB0410846A GB0410846D0 (en) | 2004-05-14 | 2004-05-14 | Treatment of neurodegenerative conditions |
| PCT/GB2004/003524 WO2005018632A1 (en) | 2003-08-18 | 2004-08-13 | Treatment of neurodegenerative conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE112004001520T5 DE112004001520T5 (de) | 2006-07-06 |
| DE112004001520B4 true DE112004001520B4 (de) | 2008-04-10 |
Family
ID=34219616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE112004001520T Expired - Fee Related DE112004001520B4 (de) | 2003-08-18 | 2004-08-13 | Verwendung eines Lipidglyzerids festgelegter Struktur zur Herstellung eines Medikamentes zur Behandlung der multiplen Sklerose |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7964641B2 (https=) |
| EP (2) | EP1660071A1 (https=) |
| JP (1) | JP2007502805A (https=) |
| AU (1) | AU2004266480B2 (https=) |
| CA (1) | CA2534202C (https=) |
| CH (1) | CH698539A8 (https=) |
| DE (1) | DE112004001520B4 (https=) |
| ES (1) | ES2304094B2 (https=) |
| FI (1) | FI20060154A7 (https=) |
| GB (1) | GB2422373B (https=) |
| IS (1) | IS8246A (https=) |
| NO (1) | NO20061232L (https=) |
| WO (1) | WO2005018632A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| WO2005018632A1 (en) | 2003-08-18 | 2005-03-03 | Btg International Limited | Treatment of neurodegenerative conditions |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
| GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
| JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| US20070112592A1 (en) | 2005-11-17 | 2007-05-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Payments in providing assistance related to health |
| US10042980B2 (en) | 2005-11-17 | 2018-08-07 | Gearbox Llc | Providing assistance related to health |
| US10296720B2 (en) | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US20080004909A1 (en) * | 2005-11-30 | 2008-01-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems related to nutraceuticals |
| EP2098229A4 (en) * | 2006-12-28 | 2010-03-10 | Suntory Holdings Ltd | NERVE REGENERATION MEDIUM |
| US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
| HRP20130551T1 (xx) | 2007-03-28 | 2013-07-31 | Aker Biomarine As | Biouäśinkovite smjese kril ulja |
| BRPI0919020B8 (pt) * | 2008-09-12 | 2021-05-25 | Cryopraxis Criobiologia Ltda | uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris |
| US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
| DK2409695T3 (en) | 2010-07-05 | 2018-05-28 | Beth Israel Deaconess Medical Ct Inc | SN-2-MONOACYLGYLYCEROLS AND LIPID MALABSORPTION |
| AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
| GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
| JP2016023163A (ja) * | 2014-07-22 | 2016-02-08 | 出光興産株式会社 | γ−リノレン酸を含む神経細胞の酸化ストレス軽減剤 |
| PL3256003T5 (pl) | 2015-02-11 | 2025-11-17 | Aker Biomarine Human Ingredients As | Sposoby ekstrakcji lipidów |
| WO2016128838A2 (en) | 2015-02-11 | 2016-08-18 | Aker Biomarine Antarctic As | Lipid compositions |
| CN105468156A (zh) * | 2015-11-25 | 2016-04-06 | 新乡医学院 | 一种基于α波控制的新型异步脑-机接口系统 |
| US11406616B2 (en) | 2016-06-08 | 2022-08-09 | Sunregen Healthcare Ag | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
| KR102054401B1 (ko) * | 2018-03-26 | 2019-12-10 | 주식회사 엔지켐생명과학 | 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제 |
| JP2022505215A (ja) * | 2018-10-18 | 2022-01-14 | ディーエス バイオファーマ リミテッド | 炎症性、線維性、および増殖性状態を治療するためのｄｇｌａおよび／または１５－ｈｅｔｒｅ |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4607052A (en) * | 1983-04-15 | 1986-08-19 | Roussel-Uclaf | Triglycerides, dietetic and therapeutical applications and compositions containing them |
| EP0437524B1 (en) * | 1988-10-10 | 1992-04-15 | Novo Nordisk A/S | Triglyceride and nutritional composition comprising such triglycerides. |
| US20040266874A1 (en) * | 2001-02-08 | 2004-12-30 | Kengo Akimoto | Composition having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction |
| DE60106026T2 (de) * | 2000-06-23 | 2006-02-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen |
Family Cites Families (130)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2077371A (en) | 1937-04-13 | Synthetic drx | ||
| US655579A (en) * | 1900-02-27 | 1900-08-07 | Draper Co | Lease-forming mechanism. |
| US2617791A (en) | 1949-09-15 | 1952-11-11 | Trojan Powder Co | Recovery of valuable products from pentaerythritol mother liquor |
| US3082228A (en) | 1959-12-18 | 1963-03-19 | Escambia Chem Corp | Method for producing monoesters of polyunsaturated fatty acids |
| US3158541A (en) | 1959-12-18 | 1964-11-24 | Escambia Chem Corp | Product for reduction of blood cholesterol concentration |
| IE32979B1 (en) | 1968-03-07 | 1974-02-06 | Unilever Ltd | Spreadable fats |
| US3558656A (en) | 1968-04-19 | 1971-01-26 | Smith Kline French Lab | Glycerol trichloroethyl carbonate and derivatives |
| US3671563A (en) | 1968-04-19 | 1972-06-20 | Smith Kline French Lab | Glycerol 3-(2,2,2-trichloroethyl) carbonate |
| US3676472A (en) | 1969-07-28 | 1972-07-11 | American Home Prod | Certain linoleic and linolenic acid ester fractions of vegetable oils and derivatives thereof |
| US3748348A (en) | 1970-07-27 | 1973-07-24 | Lever Brothers Ltd | Directed-interesterified glyceridic oils having a high linoleic acid content and process for their production |
| US3671557A (en) | 1970-09-17 | 1972-06-20 | Smith Kline French Lab | 1,2-diacylglycerol 3-(2,2,2-trichloroethyl) carbonates |
| GB1370021A (en) | 1971-03-25 | 1974-10-09 | Unilever Ltd | Process for preparing usaturated carboxylic acids |
| US3855254A (en) | 1972-03-31 | 1974-12-17 | Lever Brothers Ltd | Interesterification process |
| US4058594A (en) * | 1974-04-25 | 1977-11-15 | John Williams | Immuno-suppressive agents |
| GB1506563A (en) * | 1974-04-25 | 1978-04-05 | Williams J | Immunosuppressive agents |
| US3988446A (en) | 1974-11-07 | 1976-10-26 | Abbott Laboratories | Glycerides with anti-inflammatory properties |
| US3972907A (en) | 1975-03-24 | 1976-08-03 | G. D. Searle & Co. | Anti-hyperlipidemic fatty acids and esters |
| US4048202A (en) | 1975-04-11 | 1977-09-13 | G. D. Searle & Co. | 3-O-Alkanoylglyceric acids |
| US4178299A (en) | 1978-03-27 | 1979-12-11 | Abbott Laboratories | Process for preparing 1,3-diacyl glycerols |
| DE2967049D1 (en) * | 1978-04-11 | 1984-07-19 | Efamol Ltd | Pharmaceutical and dietary composition comprising gamma-linolenic acids |
| US4181670A (en) | 1978-12-11 | 1980-01-01 | G. D. Searle & Co. | Phenyl 5Z,8Z,11Z,14Z-eicosatetraenoate and congeners |
| ATE24266T1 (de) | 1982-04-16 | 1987-01-15 | Nestle Sa | Lipidhaltige zusammensetzung fuer die orale, enterale oder parenterale ernaehrung. |
| US4701469A (en) * | 1983-04-15 | 1987-10-20 | Roussel Uclaf | Triglycerides, process for therapeutical applications and compositions containing them |
| US4701468A (en) | 1983-04-15 | 1987-10-20 | Roussel-Uclaf | Oxidized triglycerides having therapeutic utility |
| GB8404463D0 (en) | 1984-02-21 | 1984-03-28 | Efamol Ltd | Microbiological production of essential fatty acids |
| AT383130B (de) * | 1984-05-15 | 1987-05-25 | Chemie Linz Ag | Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin |
| US5077312A (en) | 1984-07-08 | 1991-12-31 | Oncogen | Biologically active lipids binding membrane receptors |
| GB2178752B (en) | 1985-07-12 | 1989-10-11 | Unilever Plc | Substitute milk fat |
| US4888324A (en) | 1985-10-01 | 1989-12-19 | Angio-Medical Corporation | Method for enhancing angiogenesis with lipid containing molecules |
| GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
| US5151291A (en) | 1985-12-27 | 1992-09-29 | Nisshin Flour Milling Co., Ltd. | Glycerides of eicosapentaenoic acid, processes for preparing the same and oil and fat products containing the same |
| US5306730A (en) | 1986-02-03 | 1994-04-26 | Kabushiki Kaisha Yakult Honsha | Botulinum toxin neutralizer |
| US5227403A (en) | 1986-10-01 | 1993-07-13 | The Nisshin Oil Mills, Ltd. | Fats and oils having superior digestibility and absorptivity |
| US4867965A (en) | 1986-10-02 | 1989-09-19 | Revlon, Inc. | Fatty acid diesters |
| FR2617161B1 (fr) | 1987-06-29 | 1989-10-27 | Azar Robert | Nouveaux glycerides d'acide gras insature et leur procede d'obtention |
| US4832975A (en) | 1987-09-29 | 1989-05-23 | The Procter & Gamble Company | Tailored triglycerides having improved autoignition characteristics |
| US5008126A (en) | 1989-06-27 | 1991-04-16 | Nabisco Brands, Inc. | Long chain diol diesters as low calorie fat mimetics |
| US5922345A (en) | 1990-12-07 | 1999-07-13 | Scotia Holdings Plc | Nutrition |
| GB9026648D0 (en) | 1990-12-07 | 1991-01-23 | Efamol Holdings | Nutrition |
| PH11992043811B1 (en) | 1991-01-24 | 2002-08-22 | Martek Corp | Arachidonic acid and methods for the production and use thereof |
| US5658767A (en) | 1991-01-24 | 1997-08-19 | Martek Corporation | Arachidonic acid and methods for the production and use thereof |
| JPH04328199A (ja) | 1991-04-26 | 1992-11-17 | Nisshin Oil Mills Ltd:The | α−リノレン酸高含有トリグリセライドの濃縮方法 |
| GB9111900D0 (en) | 1991-06-03 | 1991-07-24 | Efamol Holdings | Fatty acid compositions |
| US5674901A (en) | 1995-06-01 | 1997-10-07 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations |
| JPH05310638A (ja) | 1992-05-01 | 1993-11-22 | Idemitsu Petrochem Co Ltd | 不飽和脂肪酸トリグリセライドの製造法 |
| JPH06172263A (ja) | 1992-08-14 | 1994-06-21 | Agency Of Ind Science & Technol | 高純度アラキドン酸トリグリセリド及びその製造方法 |
| US5618955A (en) | 1992-11-30 | 1997-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fatty acid derivatives and pharmaceutical compositions containing same |
| DE69420124T2 (de) | 1993-01-15 | 2000-03-02 | Abbott Laboratories, Abbott Park | Strukturierte lipide |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| GB9301629D0 (en) | 1993-01-27 | 1993-03-17 | Scotia Holdings Plc | Formulations containing unsaturated fatty acids |
| JPH06279311A (ja) | 1993-03-26 | 1994-10-04 | Sagami Chem Res Center | プロテインキナーゼｃアイソザイムの活性化剤 |
| JPH0741421A (ja) | 1993-05-28 | 1995-02-10 | Suntory Ltd | ロイコトリエンｂ４ （ｌｔｂ４ ）による医学的症状の予防及び改善剤 |
| US20050027004A1 (en) | 1993-06-09 | 2005-02-03 | Martek Biosciences Corporation | Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions |
| US5663450A (en) | 1993-08-17 | 1997-09-02 | Cv Therapeutics | Macrophage lipid chemoattractant |
| US5668174A (en) | 1993-12-29 | 1997-09-16 | Kowa Tekuno Sachi Co., Ltd. | Method of treating hyperparathyroidism |
| JPH07309773A (ja) | 1994-05-16 | 1995-11-28 | Sagami Chem Res Center | アセチルコリン放出促進剤 |
| FR2722410B1 (fr) | 1994-07-15 | 1996-10-04 | Grinda Jean Robert | Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique |
| JP3770628B2 (ja) | 1994-08-09 | 2006-04-26 | サントリー株式会社 | 遅延型アレルギー反応を介する医学的症状の予防及び改善剤 |
| EP0707850A1 (en) | 1994-09-21 | 1996-04-24 | Scotia Holdings Plc | Use of polyunsaturated fatty acids for the manufacture of a medicament for the treatment of brest pain |
| EP0711503A3 (en) | 1994-11-14 | 1997-11-26 | Scotia Holdings Plc | Milk fortified with GLA and/or DGLA |
| US5990163A (en) | 1995-01-13 | 1999-11-23 | The Salk Institute For Biological Studies | Selective modulation of processes mediated by retinoid X receptors, and compounds useful therefor |
| US6410078B1 (en) | 1995-04-28 | 2002-06-25 | Loders-Croklaan B.V. | Triglycerides, rich in polyunsaturated fatty acids |
| KR100458659B1 (ko) | 1995-08-07 | 2005-06-27 | 산토리 가부시키가이샤 | 오메가9계불포화지방산을포함하는연골조직의이상에기인하는의학적증상의예방또는개선작용을갖는음식품및이의제조방법 |
| GB9519661D0 (en) | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
| US5776913A (en) | 1995-10-10 | 1998-07-07 | Colgate Palmolive Company | Therapeutic diet for metabolic abnormalities found in animals with lymphoma |
| US6015798A (en) | 1995-10-10 | 2000-01-18 | Colgate Palmolive Company | Method for reducing the damaging effects of radiation therapy on animal skin and mucosa |
| JP2000508645A (ja) | 1996-04-12 | 2000-07-11 | ペプテック リミテッド | ポリ不飽和脂肪酸を使用する免疫病の治療方法 |
| US5753702A (en) | 1996-05-22 | 1998-05-19 | University Of Vermont | Arachidonic acid metabolite, 16-hete |
| US6340485B1 (en) | 1996-06-03 | 2002-01-22 | Croda International Plc | Compositions and uses thereof |
| WO1997046220A1 (en) | 1996-06-03 | 1997-12-11 | Croda International Plc | Vegetable oil compositions |
| EP0914112A1 (en) | 1996-06-29 | 1999-05-12 | The Scottish Agricultural College | Improvement of male fertility with antioxidants and/or polyunsaturated fatty acids |
| GB9617847D0 (en) | 1996-08-27 | 1996-10-09 | Scotia Holdings Plc | Fatty acid treatment |
| ATE236627T1 (de) | 1996-10-11 | 2003-04-15 | Scarista Ltd | Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure |
| US6080787A (en) | 1997-02-21 | 2000-06-27 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
| JP2001516343A (ja) | 1997-02-21 | 2001-09-25 | アボツト・ラボラトリーズ | 壊死性全腸炎の発生を減少させるための方法及び組成物 |
| US6201022B1 (en) | 1997-03-27 | 2001-03-13 | Myorx, Inc. | Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid |
| US6432684B1 (en) | 1997-04-11 | 2002-08-13 | Abbott Laboratories | Human desaturase gene and uses thereof |
| US6051754A (en) | 1997-04-11 | 2000-04-18 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants |
| US5968809A (en) | 1997-04-11 | 1999-10-19 | Abbot Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
| US20020037876A1 (en) | 1998-06-25 | 2002-03-28 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| US6369252B1 (en) * | 1998-02-26 | 2002-04-09 | The University Of Georgia Research Foundation, Inc. | Structured lipids |
| CA2326766A1 (en) | 1998-04-03 | 1999-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Synthetic endogenous cannabinoids analogues and uses thereof |
| US6696584B2 (en) | 1998-05-04 | 2004-02-24 | Natural Asa | Isomer enriched conjugated linoleic acid compositions |
| US7101914B2 (en) | 1998-05-04 | 2006-09-05 | Natural Asa | Isomer enriched conjugated linoleic acid compositions |
| US6214372B1 (en) | 1998-05-04 | 2001-04-10 | Con Lin Co., Inc. | Method of using isomer enriched conjugated linoleic acid compositions |
| CN1219064C (zh) | 1998-08-04 | 2005-09-14 | 嘉吉有限公司 | 植物脂肪酸去饱和酶启动子 |
| KR100325581B1 (ko) | 1998-08-07 | 2002-08-24 | 오우택 | 아라키토닉산의리폭시게네이즈대사결과물질을함유하는진통제용조성물 |
| WO2000009118A1 (en) | 1998-08-13 | 2000-02-24 | The Wistar Institute | Methods for reducing atherosclerotic plaques |
| GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| JP3779505B2 (ja) | 1999-08-24 | 2006-05-31 | 花王株式会社 | 油脂組成物 |
| US6426367B1 (en) | 1999-09-09 | 2002-07-30 | Efa Sciences Llc | Methods for selectively occluding blood supplies to neoplasias |
| US6340705B1 (en) | 1999-09-10 | 2002-01-22 | Monsanto Technology, Llc | Use of α-linolenic acid metabolites for treatment or prevention of cancer |
| DE60027376T2 (de) | 1999-09-30 | 2007-02-01 | Loders Croklaan B.V. | Zusammensetzungen, enthaltend Pinolensäure sowie deren Verwendung zur Gesundheitserhaltung |
| GB9923738D0 (en) | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
| US20010047036A1 (en) | 1999-12-17 | 2001-11-29 | Vanderhoof Jon A. | Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome |
| EG22407A (en) | 2000-02-17 | 2003-01-29 | Iams Company | Method for improving bone modeling and chondrocyte functioning in growing canines |
| US6361806B1 (en) | 2000-02-23 | 2002-03-26 | Michael P. Allen | Composition for and method of topical administration to effect changes in subcutaneous adipose tissue |
| EP1129711B1 (en) | 2000-02-24 | 2004-01-28 | Unilever N.V. | Pinolenic acid against diabetes |
| GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
| JP2002047176A (ja) | 2000-08-04 | 2002-02-12 | Idemitsu Technofine Co Ltd | ＩｇＥ産生抑制剤 |
| US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| FR2815227B1 (fr) | 2000-10-17 | 2003-04-11 | Schwartz Laboratoires Robert | Composition anti-stress destinee a etre incorporee principalement a des vehicules nutritionnels |
| NO310176B1 (no) | 2000-11-13 | 2001-06-05 | Wadlund As | Sammensetning for hud som inneholder kitosan-konjugert CLA og kitosankonjugert vitamin A eller et <beta>-cyklodekstrin-konjugertvitamin A samt fremgangsmåte for fremstilling og anvendelse avdenne |
| US6528040B1 (en) | 2001-01-18 | 2003-03-04 | Maurine Pearson | EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic |
| EP1372641A4 (en) | 2001-03-05 | 2004-08-25 | Stephen P Ernest | ENTERAL FORMULATION |
| SK14502003A3 (en) | 2001-05-30 | 2004-10-05 | Laxdale Ltd | Coenzyme Q and eicosapentaenoic acid |
| DE60235303D1 (de) * | 2001-07-02 | 2010-03-25 | Suntory Holdings Ltd | Verfahren zur herstellung von fett mit triglyceridhaltiger hochungesättigter fettsäure |
| EP1285590A1 (en) | 2001-08-08 | 2003-02-26 | Société des Produits Nestlé S.A. | Lipid blends |
| AU784852B2 (en) | 2001-08-10 | 2006-07-06 | Mars, Incorporated | Canine support diet |
| US20030032674A1 (en) * | 2001-08-13 | 2003-02-13 | Hwang Daniel H. | Use of unsaturated fatty acids to treat severe inflammatory diseases |
| NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| US6677470B2 (en) | 2001-11-20 | 2004-01-13 | Natural Asa | Functional acylglycerides |
| ITMI20012732A1 (it) | 2001-12-20 | 2003-06-20 | Health Pharma S R L | Integratore alimentare per neuropatici |
| AUPS082102A0 (en) | 2002-03-01 | 2002-03-21 | Women's And Children's Hospital | Therapeutic properties of oils |
| NZ535549A (en) | 2002-03-08 | 2006-02-24 | Monsanto Technology Llc | Treatment and prevention of inflammatory disorders |
| US20040048926A1 (en) | 2002-03-15 | 2004-03-11 | Hoffman Dennis Robert | Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months |
| US20060094784A1 (en) | 2002-05-17 | 2006-05-04 | Masataka Kagawa | Tgf-alpha expression inhibitors |
| US7335481B2 (en) | 2002-07-24 | 2008-02-26 | Christer Owman | Methods of identifying compounds that affect a fatty acid cell-surface receptor |
| EP1569620A4 (en) | 2002-10-30 | 2006-03-22 | Spherics Inc | NANOPARTICULAR BIOACTIVE AGENTS |
| US7074418B2 (en) | 2002-11-18 | 2006-07-11 | Changaris David G | Conjugated fatty acid based emulsion and methods for preparing and using same |
| WO2004048504A2 (en) | 2002-11-26 | 2004-06-10 | George Washington University | Method and composition with conjugated linoleic acid esters |
| US6841573B2 (en) | 2002-11-27 | 2005-01-11 | Molecular Nutrition | Use of arachidonic acid as a method of increasing skeletal muscle mass |
| US20040209953A1 (en) * | 2002-12-06 | 2004-10-21 | Wai Lee Theresa Siu-Ling | Glyceride compositions and methods of making and using same |
| US20040208939A1 (en) | 2003-04-18 | 2004-10-21 | Barry Sears | Novel dietary compositions to reduce inflammation |
| GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| US20050025744A1 (en) * | 2003-08-01 | 2005-02-03 | Lane Thomas E. | Combination therapies for multiple sclerosis |
| WO2005018632A1 (en) | 2003-08-18 | 2005-03-03 | Btg International Limited | Treatment of neurodegenerative conditions |
| US20070105954A1 (en) | 2003-12-31 | 2007-05-10 | Ingennus Limited | Formulation containing a carboxylic acid or an ester thereof |
| GB0504362D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
-
2004
- 2004-08-13 WO PCT/GB2004/003524 patent/WO2005018632A1/en not_active Ceased
- 2004-08-13 CH CH00249/06A patent/CH698539A8/de not_active IP Right Cessation
- 2004-08-13 ES ES200650014A patent/ES2304094B2/es not_active Expired - Fee Related
- 2004-08-13 CA CA2534202A patent/CA2534202C/en not_active Expired - Fee Related
- 2004-08-13 GB GB0603646A patent/GB2422373B/en not_active Expired - Fee Related
- 2004-08-13 US US10/567,778 patent/US7964641B2/en not_active Expired - Fee Related
- 2004-08-13 JP JP2006523678A patent/JP2007502805A/ja active Pending
- 2004-08-13 AU AU2004266480A patent/AU2004266480B2/en not_active Ceased
- 2004-08-13 EP EP04768085A patent/EP1660071A1/en not_active Withdrawn
- 2004-08-13 EP EP11157375A patent/EP2324828A1/en not_active Withdrawn
- 2004-08-13 FI FI20060154A patent/FI20060154A7/fi not_active Application Discontinuation
- 2004-08-13 DE DE112004001520T patent/DE112004001520B4/de not_active Expired - Fee Related
-
2006
- 2006-01-19 IS IS8246A patent/IS8246A/is unknown
- 2006-03-17 NO NO20061232A patent/NO20061232L/no not_active Application Discontinuation
-
2009
- 2009-12-31 US US12/654,780 patent/US20100113810A1/en not_active Abandoned
- 2009-12-31 US US12/654,779 patent/US20100113595A1/en not_active Abandoned
-
2012
- 2012-02-01 US US13/363,705 patent/US20120142775A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4607052A (en) * | 1983-04-15 | 1986-08-19 | Roussel-Uclaf | Triglycerides, dietetic and therapeutical applications and compositions containing them |
| EP0437524B1 (en) * | 1988-10-10 | 1992-04-15 | Novo Nordisk A/S | Triglyceride and nutritional composition comprising such triglycerides. |
| DE60106026T2 (de) * | 2000-06-23 | 2006-02-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen |
| US20040266874A1 (en) * | 2001-02-08 | 2004-12-30 | Kengo Akimoto | Composition having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction |
Non-Patent Citations (3)
| Title |
|---|
| J. Amer. Oil Chem. Soc., 75(1998)4, 507-510 * |
| J. Amer. Oil Chem. Soc., 78(2001)6, 611-616 * |
| US 20040266874 A1 (Prio JP 2001235519, veröffentlicht am 21.02.03 als JP 2003048831 A) * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2304094A1 (es) | 2008-09-01 |
| GB2422373B (en) | 2008-05-21 |
| NO20061232L (no) | 2006-05-15 |
| AU2004266480A1 (en) | 2005-03-03 |
| IS8246A (is) | 2006-01-19 |
| ES2304094B2 (es) | 2010-10-14 |
| WO2005018632A1 (en) | 2005-03-03 |
| CH698539A8 (de) | 2009-10-15 |
| US20100113595A1 (en) | 2010-05-06 |
| GB2422373A (en) | 2006-07-26 |
| GB0603646D0 (en) | 2006-04-05 |
| CA2534202A1 (en) | 2005-03-03 |
| US20080194684A1 (en) | 2008-08-14 |
| FI20060154L (fi) | 2006-02-17 |
| DE112004001520T5 (de) | 2006-07-06 |
| CA2534202C (en) | 2012-01-17 |
| FI20060154A7 (fi) | 2006-05-11 |
| US7964641B2 (en) | 2011-06-21 |
| AU2004266480B2 (en) | 2011-03-03 |
| CH698539B1 (de) | 2009-08-31 |
| US20100113810A1 (en) | 2010-05-06 |
| EP2324828A1 (en) | 2011-05-25 |
| US20120142775A1 (en) | 2012-06-07 |
| JP2007502805A (ja) | 2007-02-15 |
| EP1660071A1 (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE112004001520B4 (de) | Verwendung eines Lipidglyzerids festgelegter Struktur zur Herstellung eines Medikamentes zur Behandlung der multiplen Sklerose | |
| DE60022987T2 (de) | Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält | |
| DE60212786T2 (de) | Verwendung mehrfach ungesättigter Fettsäuren zur primären Prävention kardiovaskulärer Ereignisse | |
| EP0607231B1 (de) | Verwendung einer emulsion, zur herstellung eines arzneimittels zur i.v.-verabreichung zur behandlung von hauterkrankungen | |
| AT398779B (de) | Fettsäurezusammensetzung, verfahren zu ihrer herstellung, ihre verwendung und pharmazeutische zusammensetzung, die sie enthält | |
| CH661209A5 (de) | Fettsaeurezusammensetzung. | |
| CH699430B1 (de) | Verwendung eines Triglycerid-Öls zur Herstellung eines Medikamentes für die Behandlung von Multipler Sklerose. | |
| DE68903378T2 (de) | Hemmung der zellenadhaesion. | |
| DE202015009883U1 (de) | Eicosapentaensäurealkylester enthaltende Zusammensetzung | |
| CH681891A5 (https=) | ||
| US3158541A (en) | Product for reduction of blood cholesterol concentration | |
| CH627761A5 (en) | Process for the preparation of 17 beta esters of testosterone and 5 alpha-dihydrotestosterone | |
| US8114903B2 (en) | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids | |
| US20090023807A1 (en) | Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters | |
| CN1867328B (zh) | 脂类甘油酯用于制备治疗神经变性状况的药物的应用 | |
| GB2442161A (en) | Treatment of neurodegenerative conditions | |
| GB2442164A (en) | Treatment of neurodegenerative conditions | |
| HK1110227B (en) | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids | |
| HK1000997B (en) | Use of fatty acids for increasing gut calcium absorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law |
Ref document number: 112004001520 Country of ref document: DE Date of ref document: 20060706 Kind code of ref document: P |
|
| 8125 | Change of the main classification |
Ipc: C07C 69/003 AFI20051017BHDE |
|
| 8364 | No opposition during term of opposition | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Effective date: 20140301 |